Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 151-158 , May 2011

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

  • Fredrick L. Dunn

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, TX, USA
    • Corresponding Author InformationCorresponding author. Center for Human Nutrition, University of Texas Southwestern, Dallas, TX 75230-9052, USA.
    • ,
  • Linda S. Higgins

      Affiliations

    • InteKrin Therapeutics Inc., Los Altos, CA, USA
    • ,
  • Jill Fredrickson

      Affiliations

    • Pharsight Corporation, Mountain View, CA, USA
    • ,
  • Alex M. DePaoli

      Affiliations

    • InteKrin Therapeutics Inc., Los Altos, CA, USA
    • ,
  • for the INT131-004 study group

Received 17 March 2010 ,Revised 21 June 2010 ,Accepted 30 June 2010.

References 

  1. Actos, 2008 Actos ® (pioglitazone) label approved on 12/11/2008 for ACTOS NDA no 021073. Internet: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021073s034lbl.pdf (accessed July 10, 2009).
  2. Avandia, 2008 Avandia ® (rosiglitazone) label approved on 10/20/2008 for AVANDIA, NDA no. 021071. Internet: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021071s034lbl.pdf (accessed July 10, 2009).
  3. Berger JP, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409–435
  4. Berger JP, Petro A, Macnaul KL, Kelly LJ, Zhang BB, Richards K, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol. 2003;17:662–676
  5. DePaoli AM, Dunn F, Fredrickson J, Higgins L. INT131: a selective PPARγ modulator (SPPARM) significantly lowers glucose without typical thiazolidinedione (TZD) side effects in patients with type 2 diabetes. Diabetes. 2009;59(S1):A31–2
  6. DePaoli AM, Henry RR, Dunn FL, Pakele PC, Mantzoros CS, Higgins LS for the INT131-007 study group. Impact of INT131, a selective PPARγ modulator (SPPARM) on glycemic control in patients with type 2 diabetes in a 24 week phase 2b study. Diabetologia. 2009;52(S1):S342
  7. DePaoli AM, Higgins LS. INT131, a non-TZD selective PPARγ modulator (SPPARM), does not cause toxicities typical of TZD full PPARγ agonists following 6-month high dose treatment of rats or monkeys. Diabetologia. 2008;51(S1):S369
  8. Dunn F, Higgins L, DePaoli A. INT131: a selective PPARγ modulator (SPPARM) for type 2 diabetes mellitus. Diabetes. 2008;57(S1):A149
  9. Higgins LS, Mantzoros CS. The development of INT131 as a selective PPARγ modulator: approach to a safer insulin sensitizer. PPAR Res. 2008;936906–936915
  10. Kersey K, Floren LC, Pendleton B, Stempien MJ, Buchanan J, Dunn F. T0903131, a selective modulator of PPARγ activity, increases adiponectin levels in healthy subjects. Diabetes. 2004;53(S2):A156
  11. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinic trials. Lancet. 2007;370:1129–1136
  12. Lebovitz HD, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metabol. 2001;86:280–288
  13. Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, et al. INT131: a selective modulator of PPARγ. J Mol Biol. 2009;386:1301–1311
  14. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema and type 2 diabetes mellitus: incidence, pathophysiology, and clinical implications. Endocrine Practice. 2003;9:406–416
  15. Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Annals of Pharmacotherapy. 2007;41:2014–2018
  16. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–263
  17. Olefsky JM. Treatment of insulin resistance with peroxidase proliferator-activated receptor gamma agonists. J Clin Invest. 2000;106:467–472
  18. Pavo I, Jermendy G, Varkonyi TT, Kerenyl Z, Gyimes A, Shoustov S, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:1637–1647
  19. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardham R, Fried M. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43:278–284
  20. Rohatagi S, Carrothers TJ, Jin JY, Jusko WJ, Khariton T, Walker J, et al. Model-based development of a PPARg agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J Clin Pharmacol. 2008;48:1420–1429
  21. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007;1771:1065–1081
  22. Waites CR, Dominick MA, Sanderson TP, Schilling BE. Nonclinical safety evaluation of muraglitazar, a novel PPARα/γ agonist. Toxicol Sci. 2007;100:248–258
  23. Yki-Javinen H. Thiazolidinediones. New Engl J Med. 2004;351:1106–1118
  24. Yu JG, Javorschi S, Hevener Al, Kruszynska YT, Norman RA, Sinha M, et al. The effect of thiazolidienediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968–2974
  25. Zhang F, Lavan BE, Gregoire FM. Selective modulators of PPAR-gamma activity: Molecular aspects related to obesity and side-effects. PPAR Res. 2007;32696

☆ Clinical Trial Registration: NCT00952445.

☆☆ Disclosures: Dr. Dunn is a member of the Scientific Advisory Board of InteKrin Therapeutics Inc. Drs Higgins and DePaoli are employees of InteKrin Therapeutics. Dr. Fredrickson was previously employed by Pharsight.

PII: S1056-8727(10)00071-1

doi: 10.1016/j.jdiacomp.2010.06.006

Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 151-158 , May 2011

Article Tools

* Image Usage & Resolution